Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Dual inhibitors of protein kinases CK2 and PIM-1 show promise for inducing cancer cell apoptosis.
• Existing selective CK2/PIM-1 inhibitors lack cell permeability, limiting their therapeutic application.
• There is a need for cell-permeable dual inhibitors targeting CK2 and PIM-1.

Purpose of the Study:

• To develop a selective, cell-permeable dual inhibitor of CK2 and PIM-1.
• To elucidate the structural basis for the potency and selectivity of the novel inhibitor.
• To evaluate the compound's efficacy in inducing cancer cell apoptosis and its pharmacological potential.

Main Methods:

• Derivatization of the CK2 inhibitor TBI with a deoxyribose moiety to create TDB.
• Synthesis and evaluation of TDB analogs to understand structure-activity relationships.
• X-ray crystallography to determine the 3D structure of the TDB/CK2 complex.
• Assessment of TDB's cytotoxic effects, apoptosis induction, and kinase inhibition in cancer cells.

Main Results:

• TDB was generated as a selective, cell-permeable inhibitor of both CK2 and PIM-1.
• The 3D structure of the TDB/CK2 complex was solved at 1.25 Å resolution, revealing key structural features.
• TDB effectively induces apoptosis in cancer cells, with efficacy superior to combinations of individual inhibitors or CX4945.
• Cancer cells exhibit higher susceptibility to TDB than non-cancer cells, even in multi-drug resistant backgrounds.

Conclusions:

• TDB is a potent and selective cell-permeable dual inhibitor of CK2 and PIM-1.
• The structural insights gained contribute to understanding kinase inhibition mechanisms.
• TDB demonstrates significant pharmacological potential as an anti-cancer agent due to its apoptosis-inducing properties and efficacy against resistant cells.